Rep. Carolyn Maloney (D-NY) (Bill Clark/CQ Roll Call via AP Images)

House, Sen­ate Dems in­tro­duce leg­is­la­tion to com­bat 'abu­sive' phar­ma busi­ness prac­tices

In the af­ter­math of Con­gress in­tro­duc­ing leg­is­la­tion al­low­ing Medicare to ne­go­ti­ate drug prices — which cur­rent­ly re­mains in lim­bo af­ter the failed pas­sage of the Build Back Bet­ter Act — some con­gres­sion­al Dems have shift­ed gears and have put their tar­gets on oth­er phar­ma busi­ness prac­tices.

House Over­sight Com­mit­tee Chair Car­olyn Mal­oney led a group of De­mo­c­rat col­leagues and in­tro­duced three bills on Thurs­day to tar­get “busi­ness prac­tices phar­ma­ceu­ti­cal com­pa­nies use to sup­press com­pe­ti­tion, main­tain mar­ket mo­nop­o­lies, and keep drug prices high,” a state­ment from the of­fi­cials said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA